{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T10:06:54Z","timestamp":1753870014809,"version":"3.41.2"},"reference-count":10,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2020,3,31]],"date-time":"2020-03-31T00:00:00Z","timestamp":1585612800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bpspubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology Res &amp; Perspec"],"published-print":{"date-parts":[[2020,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Crizotinib (XALKORI<jats:sup>\u00ae<\/jats:sup>) is indicated for anaplastic lymphoma kinase\u2010positive and ROS1\u2010positive advanced non\u2010small cell lung cancer. This study evaluated the distribution of the crizotinib patient information brochure (PIB) in Europe and patient knowledge of the key messages in the PIB. A cross\u2010sectional survey was conducted in 10 European countries among patients who received crizotinib to ascertain whether each patient received and read the PIB, and his\/her knowledge of its key messages on hepatotoxicity, interstitial lung disease\/pneumonitis, QTc prolongation, bradycardia, and vision disorders. Of the 341 patients contacted, 40 responded (11.7%), and 39 patients were eligible. A total of 77% of respondents acknowledged receiving the PIB, of which, 93% reported reading it. Knowledge of the individual side effects ranged from 36% to 85%, and precautions for use ranged from 56% to 67%. Understanding the reasons for calling a physician ranged from 54% to 85%. Knowledge of each of the 6 key side effects was greater among readers of the PIB compared to non\u2010readers or respondents who did not recall receiving the PIB. Approximately three\u2010quarters of survey respondents recalled receiving the crizotinib PIB and respondents who read the PIB were more knowledgeable of the key side effects of crizotinib than those who did not read or receive. Caution should be taken in generalizing these results because of the potential for selection bias and small sample size. These survey results suggest that the crizotinib PIB may be an effective risk communication tool for crizotinib\u2010treated patients in Europe.<\/jats:p>","DOI":"10.1002\/prp2.570","type":"journal-article","created":{"date-parts":[[2020,3,31]],"date-time":"2020-03-31T07:55:57Z","timestamp":1585641357000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effect of the patient information brochure in communicating the risks associated with crizotinib treatment to patients with non\u2010small cell lung cancer (NSCLC) in Europe"],"prefix":"10.1002","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4643-5029","authenticated-orcid":false,"given":"Kui","family":"Huang","sequence":"first","affiliation":[{"name":"Epidemiology, Worldwide Safety and Regulatory Pfizer Inc New York NY USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Terri","family":"Madison","sequence":"additional","affiliation":[{"name":"Real World Strategy and Analytics Mapi, an ICON plc company Lexington KY USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beatrice","family":"Wehler","sequence":"additional","affiliation":[{"name":"Department of Radio\u2010Oncology University Hospital Saarland Homburg Germany"},{"name":"3rd Medical Department University Medical Center Mainz Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcello","family":"Tiseo","sequence":"additional","affiliation":[{"name":"Department of Medicine and Surgery University of Parma Parma Italy"},{"name":"Medical Oncology Unit University Hospital of Parma Parma Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keith D.","family":"Wilner","sequence":"additional","affiliation":[{"name":"Oncology Clinical Development Pfizer Inc La Jolla CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingping","family":"Mo","sequence":"additional","affiliation":[{"name":"Epidemiology, Worldwide Safety and Regulatory Pfizer Inc New York NY USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2020,3,31]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21492"},{"key":"e_1_2_10_3_1","unstructured":"IARC 2018.http:\/\/gco.iarc.fr\/today\/data\/factsheets\/cancers\/15-Lung-fact-sheet.pdf(accessed 01 November 2018)."},{"key":"e_1_2_10_4_1","unstructured":"Cancer Research UK.http:\/\/www.cancerresearchuk.org\/about-cancer\/lung-cancer\/stages-types-grades\/types(accessed 01 December 2017)."},{"key":"e_1_2_10_5_1","unstructured":"HowladerN NooneAM KrapchoM et al. (eds).SEER Cancer Statistics Review 1975\u20132013 National Cancer Institute. Bethesda MD http:\/\/seer.cancer.gov\/csr\/1975_2013\/ based on November 2015 SEER data submission posted to the SEER web site April 2016."},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2010.28.15_suppl.10533"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-018-0662-2"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.3400"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-016-0501-2"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-013-0126-7"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0202865"}],"container-title":["Pharmacology Research &amp; Perspectives"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fprp2.570","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/prp2.570","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/prp2.570","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/prp2.570","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,7]],"date-time":"2023-09-07T06:41:20Z","timestamp":1694068880000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1002\/prp2.570"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,31]]},"references-count":10,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["10.1002\/prp2.570"],"URL":"https:\/\/doi.org\/10.1002\/prp2.570","archive":["Portico"],"relation":{},"ISSN":["2052-1707","2052-1707"],"issn-type":[{"type":"print","value":"2052-1707"},{"type":"electronic","value":"2052-1707"}],"subject":[],"published":{"date-parts":[[2020,3,31]]},"assertion":[{"value":"2019-10-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-01-15","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-03-31","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e00570"}}